VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection

Cancer Cell

Volumn 28, Issue 2, 2015, Pages 210-224

  Arulanandam, Rozanne ^a   Batenchuk, Cory ^a   Angarita, Fernando A ^b   Ottolino Perry, Kathryn ^b   Cousineau, Sophie ^a   Mottashed, Amelia ^a   Burgess, Emma ^a   Falls, Theresa J ^a   De Silva, Naomi ^a   Tsang, Jovian ^a   Howe, Grant A ^a   Bourgeois Daigneault, Marie Claude ^a   Conrad, David P ^a   Daneshmand, Manijeh ^a   Breitbach, Caroline J ^c   Kirn, David H ^c   Raptis, Leda ^f   Sad, Subash ^g   Atkins, Harold ^a   Huh, Michael S ^a   Diallo, Jean Simon ^a   Lichty, Brian D ^d   Ilkow, Carolina S ^a   Le Boeuf, Fabrice ^a   Addison, Christina L ^a   McCart, J Andrea ^b,e   Bell, John C ^a   more..

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c SillaJen Biotherapeutics   (United States)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f QUEEN S UNIVERSITY   (Canada)

^g UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; BEVACIZUMAB; BRIVANIB; CASPASE 3; INTERFERON; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCLONAL ANTIBODY DC101; ONCOLYTIC VIRUS; RECOMBINANT VASCULOTROPIN; STAT1 PROTEIN; STAT3 PROTEIN; VASCULOTROPIN 165; PRDM1 PROTEIN, HUMAN; PRDM1 PROTEIN, MOUSE; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ADAPTIVE IMMUNITY; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL DIFFERENTIATION; COLON CARCINOMA; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME REPRESSION; GENE ONTOLOGY; GENE SILENCING; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; VACCINIA; VACCINIA VIRUS; VASCULAR REMODELING; VIRAL TROPISM; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS VIRULENCE; WOUND HEALING; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL LINE; DRUG EFFECTS; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETICS; HOST PATHOGEN INTERACTION; METABOLISM; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTION INITIATION; TUMOR CELL LINE; VASCULARIZATION; VIROLOGY;

VACCINIA VIRUS;

ANIMALS; CELL LINE; CELL LINE, TUMOR; CELLS, CULTURED; GENE EXPRESSION; GENE EXPRESSION PROFILING; HOST-PATHOGEN INTERACTIONS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ONCOLYTIC VIRUSES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; VACCINIA VIRUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84939471765     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.06.009     Document Type: Article

References (48)

1. Assi H.H., Paran C., VanderVeen N., Savakus J., Doherty R., Petruzzella E., Hoeschele J.D., Appelman H., Raptis L., Mikkelsen T., et al. Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy. J. Pharmacol. Exp. Ther. 2014, 349:458-469.
2. Barnes N.A., Stephenson S., Cocco M., Tooze R.M., Doody G.M. BLIMP-1 and STAT3 counterregulate microRNA-21 during plasma cell differentiation. J. Immunol. 2012, 189:253-260.
3. Bell J., McFadden G. Viruses for tumor therapy. Cell Host Microbe 2014, 15:260-265.
4. Breitbach C.J., De Silva N.S., Falls T.J., Aladl U., Evgin L., Paterson J., Sun Y.Y., Roy D.G., Rintoul J.L., Daneshmand M., et al. Targeting tumor vasculature with an oncolytic virus. Mol. Ther. 2011, 19:886-894.
5. Breitbach C.J., Burke J., Jonker D., Stephenson J., Haas A.R., Chow L.Q.M., Nieva J., Hwang T.-H., Moon A., Patt R., et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011, 477:99-102.
6. Breitbach C.J., Arulanandam R., De Silva N., Thorne S.H., Patt R., Daneshmand M., Moon A., Ilkow C., Burke J., Hwang T.-H., et al. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res. 2013, 73:1265-1275.
7. Brun J., McManus D., Lefebvre C., Hu K., Falls T., Atkins H., Bell J.C., McCart J.A., Mahoney D., Stojdl D.F. Identification of genetically modified Maraba virus as an oncolytic rhabdovirus. Mol. Ther. 2010, 18:1440-1449.
8. Cai Z.W., Zhang Y., Borzilleri R.M., Qian L., Barbosa S., Wei D., Zheng X., Wu L., Fan J., Shi Z., et al. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J. Med. Chem. 2008, 51:1976-1980.
9. Chang H.Y., Sneddon J.B., Alizadeh A.A., Sood R., West R.B., Montgomery K., Chi J.-T., van de Rijn M., Botstein D., Brown P.O. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2004, 2:E7.
10. Chung A.S., Lee J., Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat. Rev. Cancer 2010, 10:505-514.
11. Dejana E. Endothelial cell-cell junctions: happy together. Nat. Rev. Mol. Cell Biol. 2004, 5:261-270.
12. Doody G.M., Stephenson S., McManamy C., Tooze R.M. PRDM1/BLIMP-1 modulates IFN-gamma-dependent control of the MHC class I antigen-processing and peptide-loading pathway. J. Immunol. 2007, 179:7614-7623.
13. Eden E., Navon R., Steinfeld I., Lipson D., Yakhini Z. GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics 2009, 10:48.
14. Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., Bruns C.J., Zuelke C., Farkas S., Anthuber M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 2002, 8:128-135.
15. Ilkow C.S., Swift S.L., Bell J.C., Diallo J.-S. From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancer. PLoS Pathog. 2014, 10:e1003836.
16. Inder M.K., Ueda N., Mercer A.A., Fleming S.B., Wise L.M. Bovine papular stomatitis virus encodes a functionally distinct VEGF that binds both VEGFR-1 and VEGFR-2. J. Gen. Virol. 2007, 88:781-791.
17. Keller A.D., Maniatis T. Identification and characterization of a novel repressor of beta-interferon gene expression. Genes Dev. 1991, 5:868-879.
18. Keyes K.A., Mann L., Cox K., Treadway P., Iversen P., Chen Y.-F., Teicher B.A. Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology. Cancer Chemother. Pharmacol. 2003, 51:321-327.
19. Kim J.H., Oh J.Y., Park B.H., Lee D.E., Kim J.S., Park H.E., Roh M.S., Je J.E., Yoon J.H., Thorne S.H., et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol. Ther. 2006, 14:361-370.
20. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
21. Liang W.-C., Wu X., Peale F.V., Lee C.V., Meng Y.G., Gutierrez J., Fu L., Malik A.K., Gerber H.-P., Ferrara N., Fuh G. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J. Biol. Chem. 2006, 281:951-961.
22. Lichty B.D., Breitbach C.J., Stojdl D.F., Bell J.C. Going viral with cancer immunotherapy. Nat. Rev. Cancer 2014, 14:559-567.
23. Littlefield S.L., Baird M.C., Anagnostopoulou A., Raptis L. Synthesis, characterization and Stat3 inhibitory properties of the prototypical platinum(IV) anticancer drug, [PtCl3(NO2)(NH3)2] (CPA-7). Inorg. Chem. 2008, 47:2798-2804.
24. Masood R., Cesarman E., Smith D.L., Gill P.S., Flore O. Human herpesvirus-8-transformed endothelial cells have functionally activated vascular endothelial growth factor/vascular endothelial growth factor receptor. Am. J. Pathol. 2002, 160:23-29.
25. Matsumoto T., Claesson-Welsh L. VEGF receptor signal transduction. Sci. STKE 2001, 2001:re21.
26. Meyer M., Clauss M., Lepple-Wienhues A., Waltenberger J., Augustin H.G., Ziche M., Lanz C., Büttner M., Rziha H.J., Dehio C. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J. 1999, 18:363-374.
27. Motz G.T., Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat. Rev. Immunol. 2011, 11:702-711.
28. Ottolino-Perry K., Tang N., Head R., Ng C., Arulanandam R., Angarita F.A., Acuna S.A., Chen Y., Bell J., Dacosta R.S., McCart J.A. Tumor vascularization is critical for oncolytic vaccinia virus treatment of peritoneal carcinomatosis. Int. J. Cancer 2014, 134:717-730.
29. Pedersen T.X., Leethanakul C., Patel V., Mitola D., Lund L.R., Danø K., Johnsen M., Gutkind J.S., Bugge T.H. Laser capture microdissection-based in vivo genomic profiling of wound keratinocytes identifies similarities and differences to squamous cell carcinoma. Oncogene 2003, 22:3964-3976.
30. Pfaffl M.W., Tichopad A., Prgomet C., Neuvians T.P. Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper--Excel-based tool using pair-wise correlations. Biotechnol. Lett. 2004, 26:509-515.
31. Reinhardt B., Schaarschmidt P., Bossert A., Lüske A., Finkenzeller G., Mertens T., Michel D. Upregulation of functionally active vascular endothelial growth factor by human cytomegalovirus. J. Gen. Virol. 2005, 86:23-30.
32. Rintoul J.L., Lemay C.G., Tai L.-H., Stanford M.M., Falls T.J., de Souza C.T., Bridle B.W., Daneshmand M., Ohashi P.S., Wan Y., et al. ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic. Mol. Ther. 2012, 20:1148-1157.
33. Riss J., Khanna C., Koo S., Chandramouli G.V.R., Yang H.H., Hu Y., Kleiner D.E., Rosenwald A., Schaefer C.F., Ben-Sasson S.A., et al. Cancers as wounds that do not heal: differences and similarities between renal regeneration/repair and renal cell carcinoma. Cancer Res. 2006, 66:7216-7224.
34. Robinson N., McComb S., Mulligan R., Dudani R., Krishnan L., Sad S. Type I interferon induces necroptosis in macrophages during infection with Salmonella enterica serovar Typhimurium. Nat. Immunol. 2012, 13:954-962.
35. Schäfer M., Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat. Rev. Mol. Cell Biol. 2008, 9:628-638.
36. Schoggins J.W., Wilson S.J., Panis M., Murphy M.Y., Jones C.T., Bieniasz P., Rice C.M. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011, 472:481-485.
37. Siddiquee K., Zhang S., Guida W.C., Blaskovich M.A., Greedy B., Lawrence H.R., Yip M.L.R., Jove R., McLaughlin M.M., Lawrence N.J., et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Natl. Acad. Sci. USA 2007, 104:7391-7396.
38. Stojdl D.F., Lichty B.D., tenOever B.R., Paterson J.M., Power A.T., Knowles S., Marius R., Reynard J., Poliquin L., Atkins H., et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003, 4:263-275.
39. Suehiro J., Hamakubo T., Kodama T., Aird W.C., Minami T. Vascular endothelial growth factor activation of endothelial cells is mediated by early growth response-3. Blood 2010, 115:2520-2532.
40. Turkson J., Bowman T., Adnane J., Zhang Y., Djeu J.Y., Sekharam M., Frank D.A., Holzman L.B., Wu J., Sebti S., Jove R. Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Mol. Cell. Biol. 1999, 19:7519-7528.
41. Ueda N., Wise L.M., Stacker S.A., Fleming S.B., Mercer A.A. Pseudocowpox virus encodes a homolog of vascular endothelial growth factor. Virology 2003, 305:298-309.
42. Vultur A., Cao J., Arulanandam R., Turkson J., Jove R., Greer P., Craig A., Elliott B., Raptis L. Cell-to-cell adhesion modulates Stat3 activity in normal and breast carcinoma cells. Oncogene 2004, 23:2600-2616.
43. Wietecha M.S., Cerny W.L., DiPietro L.A. Mechanisms of vessel regression: toward an understanding of the resolution of angiogenesis. Curr. Top. Microbiol. Immunol. 2013, 367:3-32.
44. Wise L.M., Veikkola T., Mercer A.A., Savory L.J., Fleming S.B., Caesar C., Vitali A., Makinen T., Alitalo K., Stacker S.A. Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1. Proc. Natl. Acad. Sci. USA 1999, 96:3071-3076.
45. Witte L., Hicklin D.J., Zhu Z., Pytowski B., Kotanides H., Rockwell P., Böhlen P. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev. 1998, 17:155-161.
46. Yasuda T., Kometani K., Takahashi N., Imai Y., Aiba Y., Kurosaki T. ERKs induce expression of the transcriptional repressor Blimp-1 and subsequent plasma cell differentiation. Sci. Signal. 2011, 4:ra25.
47. Yu H., Kortylewski M., Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 2007, 7:41-51.
48. Zhai Y., Ni J., Jiang G.W., Lu J., Xing L., Lincoln C., Carter K.C., Janat F., Kozak D., Xu S., et al. VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J. 1999, 13:181-189.